Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32454631)

  • 1. Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients with Non-Small Cell Lung Cancer.
    Işcan M; Ada AO
    Turk J Pharm Sci; 2017 Dec; 14(3):319-323. PubMed ID: 32454631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 expression (CYP) in non-small cell lung cancer.
    Oyama T; Sugio K; Uramoto H; Kawamoto T; Kagawa N; Nadaf S; Carbone D; Yasumoto K
    Front Biosci; 2007 Jan; 12():2299-308. PubMed ID: 17127240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 gene polymorphism and cancer.
    Agundez JA
    Curr Drug Metab; 2004 Jun; 5(3):211-24. PubMed ID: 15180491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
    Bozina N; Bradamante V; Lovrić M
    Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients.
    Vasile E; Tibaldi C; Leon GL; D'Incecco A; Giovannetti E
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1189-94. PubMed ID: 25504507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD.
    Volotinen M; Mäenpää J; Kankuri E; Oksala O; Pelkonen O; Nakajima M; Yokoi T; Hakkola J
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3099-105. PubMed ID: 19324859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers.
    He X; Feng S
    Curr Drug Metab; 2015; 16(10):850-63. PubMed ID: 26652254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance.
    Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M
    J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis.
    Modugno F; Knoll C; Kanbour-Shakir A; Romkes M
    Breast Cancer Res Treat; 2003 Dec; 82(3):191-7. PubMed ID: 14703066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases.
    Daly AK
    Adv Pharmacol; 2015; 74():85-111. PubMed ID: 26233904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conditionally reprogrammed human normal bronchial epithelial cells express comparable levels of cytochromes p450 and are sensitive to BaP induction.
    Zhang Z; Bai Q; Chen Y; Ye L; Wu X; Long X; Ye L; Liu J; Li H
    Biochem Biophys Res Commun; 2018 Sep; 503(3):2132-2138. PubMed ID: 30122317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotransformation enzyme polymorphism and pesticide susceptibility.
    Eaton DL
    Neurotoxicology; 2000; 21(1-2):101-11. PubMed ID: 10794390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
    Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
    Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients.
    Karacaoğlan V; Ada AO; Bilgen S; Çetinkaya GT; Soydaş E; Kunak CS; Alpar SM; Gülhan M; Işcan M
    Turk J Med Sci; 2017 Apr; 47(2):554-562. PubMed ID: 28425245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach.
    Castell JV; Donato MT; Gómez-Lechón MJ
    Exp Toxicol Pathol; 2005 Jul; 57 Suppl 1():189-204. PubMed ID: 16092727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.
    Han ZG; Tao J; Yu TT; Shan L
    Med Sci Monit; 2017 Apr; 23():1999-2006. PubMed ID: 28442702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro assessment of the allelic variants of cytochrome P450.
    Hiratsuka M
    Drug Metab Pharmacokinet; 2012; 27(1):68-84. PubMed ID: 22041138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.
    Zhou F; Yu Z; Jiang T; Lv H; Yao R; Liang J
    Swiss Med Wkly; 2011; 141():w13275. PubMed ID: 22009704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.